Biogenerics: A Step Closer
Executive Summary
Progress on biogenerics inches along, as evidenced by deal between Barr Pharmaceuticals and PLIVA giving Barr rights to market Pliva's version of G-CSF in North America, and by the recent well-attended FDA workshop on follow-on proteins (FOPs). Barr/PlLIVA, the first company/company deal in this field in months indicates that companies still see opportunity despite last year's regulatory setbacks. The FDA workshop, while far from conclusive, hinted at a softening of positions by both opponents and proponents of biogenerics; at least they're talking the same language.